Gain Therapeutics Inc (GANX) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Gain Therapeutics Inc (US:GANX), currently being evaluated. In 2023, Gain Therapeutics Inc generated $55,180 in revenue and -$18.88 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Gain Therapeutics Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2023): $55,180
- Free Cash Flow (2023): -$18.88 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.